Details
Stereochemistry | UNKNOWN |
Molecular Formula | C21H21FN2O4S |
Molecular Weight | 416.466 |
Optical Activity | ( + ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C1CCC2=C(C1)C3=CC=CC=C3N2CC(O)=O)S(=O)(=O)C4=CC=C(F)C=C4
InChI
InChIKey=CANCTKXGRVNXFP-UHFFFAOYSA-N
InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-15)17-4-2-3-5-19(17)24(20)13-21(25)26/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17328802Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16418339
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17328802
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16418339
TM30089 is a slective CRTH2 antagonist. TM30089, displayed high selectivity for and antagonistic potency on mouse CRTH2 but lacked affinity to TP and many other receptors including the related anaphylatoxin C3a and C5a receptors, selected chemokine receptors and the cyclooxygenase isoforms 1 and 2 which are all recognized players in allergic diseases. Furthermore, TM30089 and ramatroban, the latter used as a reference herein, similarly inhibited asthma pathology in vivo by reducing peribronchial eosinophilia and mucus cell hyperplasia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5071 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22224640 |
3.6 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. | 2007 Feb 28 |
|
PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2. | 2012 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17328802
Mice: mice were treated twice daily with TM30089 (5 mg/kg orally)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22442685
1 uM of TM30089 inhibited chemotactic activation of human eosinophils, measured in eosinophil shape change assays.
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00722396
Created by
admin on Sat Dec 16 18:18:46 GMT 2023 , Edited by admin on Sat Dec 16 18:18:46 GMT 2023
|
PRIMARY | |||
|
11384493
Created by
admin on Sat Dec 16 18:18:46 GMT 2023 , Edited by admin on Sat Dec 16 18:18:46 GMT 2023
|
PRIMARY | |||
|
627865-18-3
Created by
admin on Sat Dec 16 18:18:46 GMT 2023 , Edited by admin on Sat Dec 16 18:18:46 GMT 2023
|
PRIMARY | |||
|
F449K9EB2G
Created by
admin on Sat Dec 16 18:18:46 GMT 2023 , Edited by admin on Sat Dec 16 18:18:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY